Ventyx Provides Clinical and Corporate Updates

Core Insights - Ventyx Biosciences, Inc. announced the addition of two experts to its advisory board and provided an update on its ongoing Phase 2 study of VTX2735 for recurrent pericarditis [1][2] Advisory Board Expansion - Mark McKenna, MBA, has been appointed as a Strategic Advisor; he is the founder and CEO of Mirador Therapeutics and previously led Prometheus Biosciences, which was acquired by Merck for $10.8 billion in June 2023 [3] - Dr. Peter Libby, MD, a cardiovascular specialist at Mass General Brigham, joins as a Clinical Advisor; he has significant expertise in inflammation's role in vascular diseases and led the CANTOS trial [4] Phase 2 Study Update - The ongoing Phase 2 study of VTX2735 is focused on patients with recurrent pericarditis, a condition characterized by inflammation of the pericardium, which can lead to severe pain and heart complications [5] - The study is evaluating a 150 mg BID dosing regimen with primary endpoints assessed at week 6, and eligible patients may be evaluated up to 13 weeks during an extension period [6] Strategic Developments - The company is revising its guidance for topline data release from the interim analysis of the Phase 2 RP trial to Q1 2026, allowing for the introduction of dose-ranging studies with a new once-daily formulation [2][8] - Ventyx plans to expand the Phase 2 study into Canada, the EU, and the UK, which is expected to accelerate the timeline for Phase 3 development [7][8] Future Plans - An R&D Day is scheduled for Q1 2026, where the company will present interim Phase 2 RP data and updates on the pharmacokinetic and pharmacodynamic characteristics of the new formulation [2][8]